Literature DB >> 15191504

Irritable bowel syndrome - an evidence-based approach to diagnosis.

B D Cash1, W D Chey.   

Abstract

Irritable bowel syndrome (IBS) represents one of the most common reasons for primary care visits and consultation with a gastroenterologist. It is characterized by abdominal discomfort, bloating and disturbed defecation in the absence of any identifiable physical, radiologic or laboratory abnormalities indicative of organic gastrointestinal disease. IBS is a costly disorder, responsible for significant direct and indirect costs to patients and society. Much of the cost attributed to IBS arises from the time and resources used to establish the diagnosis. Historically IBS has been viewed by many as a diagnosis of exclusion rather than as a primary diagnosis, and many patients with typical symptoms will undergo an extensive array of diagnostic tests and procedures prior to the eventual diagnosis of IBS. Recent reviews addressing the management of such patients have cast doubt on the necessity for this degree of testing. Current best evidence does not support the routine use of blood tests, stool studies, breath tests, abdominal imaging or lower endoscopy in order to exclude organic gastrointestinal disease in patients with typical IBS symptoms without alarm features. Serological testing for celiac sprue in this population may eventually prove useful but validation of studies indicating an increased prevalence of this disease in patients with suspected IBS is needed. The development and refinement of symptom-based criteria defining the clinical syndrome of IBS has greatly facilitated the diagnosis of this condition, which can be confidently diagnosed through the identification of typical symptoms, normal physical examination and the exclusion of alarm features. The presence of alarm features or persistent non-response to symptom-directed therapies should prompt a more detailed diagnostic evaluation dictated by the patient's predominant symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15191504     DOI: 10.1111/j.1365-2036.2004.02001.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  20 in total

1.  A cross-sectional study of the association between overnight call and irritable bowel syndrome in medical students.

Authors:  Malcolm Wells; Lee Roth; Morgan McWilliam; Kim Thompson; Nilesh Chande
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

Review 2.  Evaluation of lower functional gut disorders.

Authors:  Christopher N Andrews; Martin Storr
Journal:  Can J Gastroenterol       Date:  2008-07       Impact factor: 3.522

Review 3.  Irritable bowel syndrome.

Authors:  N J Talley
Journal:  Intern Med J       Date:  2006-11       Impact factor: 2.048

4.  Treatment of functional diarrhea.

Authors:  Evan S Dellon; Yehuda Ringel
Journal:  Curr Treat Options Gastroenterol       Date:  2006-07

Review 5.  Functional diarrhea.

Authors:  Michael J G Farthing
Journal:  Curr Gastroenterol Rep       Date:  2005-10

6.  Optimal management of chronic cyclical pelvic pain: an evidence-based and pragmatic approach.

Authors:  Ha Ryun Won; Jason Abbott
Journal:  Int J Womens Health       Date:  2010-08-20

7.  A case of parasite invasion of the intestinal tract: a missed diagnosis in irritable bowel syndrome.

Authors:  Kang Hun Koh; Sang Wook Kim; So Young Lee; Hee Jung Lee; Hea Min Yu; Byung Jun Jeon; Dae Hun Kwon; Soo Teik Lee
Journal:  Clin Endosc       Date:  2013-11-19

Review 8.  Treatment of irritable bowel syndrome.

Authors:  Chamara Basnayake
Journal:  Aust Prescr       Date:  2018-10-01

9.  Irritable bowel syndrome: diagnostic approaches in clinical practice.

Authors:  Eugene J Burbige
Journal:  Clin Exp Gastroenterol       Date:  2010-09-17

Review 10.  The search for reliable biomarkers of disease in multiple chemical sensitivity and other environmental intolerances.

Authors:  Chiara De Luca; Desanka Raskovic; Valeria Pacifico; Jeffrey Chung Sheun Thai; Liudmila Korkina
Journal:  Int J Environ Res Public Health       Date:  2011-07-01       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.